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ABSTRACT
Introduction Fetal growth restriction (FGR) is a major 
contributor to fetal and neonatal morbidity and mortality 
with intrauterine, neonatal and lifelong complications. This 
study explores maternal obstructive sleep apnoea (OSA) as 
a potentially modifiable risk factor for FGR. We hypothesise 
that, in pregnancies complicated by FGR, treating mothers 
who have OSA using positive airway pressure (PAP) will 
improve birth weight and neonatal outcomes.
Methods and analysis The Sleep Apnea and Fetal Growth 
Restriction study is a prospective, block- randomised, 
single- blinded, multicentre, pragmatic controlled trial. We 
enrol pregnant women aged 18–50, between 22 and 31 
weeks of gestation, with established FGR based on second 
trimester ultrasound, who do not have other prespecified 
known causes of FGR (such as congenital anomalies or 
intrauterine infection). In stage 1, participants are screened 
by questionnaire for OSA risk. If OSA risk is identified, 
participants proceed to stage 2, where they undergo home 
sleep apnoea testing. Participants are determined to have 
OSA if they have an apnoea- hypopnoea index (AHI) ≥5 (if 
the oxygen desaturation index (ODI) is also ≥5) or if they 
have an AHI ≥10 (even if the ODI is <5). These participants 
proceed to stage 3, where they are randomised to nightly 
treatment with PAP or no PAP (standard care control), 
which is maintained until delivery. The primary outcome 
is unadjusted birth weight; secondary outcomes include 
fetal growth velocity on ultrasound, enrolment- to- 
delivery interval, gestational age at delivery, birth weight 
corrected for gestational age, stillbirth, Apgar score, rate of 
admission to higher levels of care (neonatal intensive care 
unit or special care nursery) and length of neonatal stay. 
These outcomes are compared between PAP and control 
using intention- to- treat analysis.
Ethics and dissemination This study has been approved 
by the Institutional Review Boards at Washington University 
in St Louis, Missouri; Hadassah Hebrew University Medical 
Center, Jerusalem; and the University of Rochester, New 
York. Recruitment began in Washington University in 
November 2019 but stopped from March to November 
2020 due to COVID-19. Recruitment began in Hadassah 
Hebrew University in March 2021, and in the University 
of Rochester in May 2021. Dissemination plans include 
presentations at scientific conferences and scientific 
publications.
Trial registration number NCT04084990.
BACKGROUND
Fetal growth restriction (FGR) affects up 
to 10% of all pregnancies and is a major 
contributor to fetal and neonatal morbidity 
and mortality with intrauterine, neonatal 
and lifelong complications.1 2 FGR is second 
only to prematurity as a leading cause of 
perinatal morbidity and mortality. Both FGR 
and prematurity are independent risk factors 
for the development of cognitive delay, poor 
academic achievement and adult diseases 
Strengths and limitations of this study
 ► Sleep Apnea and Fetal Growth Restriction study is a 
multicentre, pragmatic trial conducted in a tertiary 
care setting.
 ► Studying patients with both fetal growth restric-
tion and home sleep apnoea testing- diagnosed 
obstructive sleep apnoea (OSA) increases the po-
tential for benefit from the intervention but limits 
generalisability.
 ► The intervention is positive airway pressure, a 
routine, safe and effective therapy for OSA in non- 
pregnant populations.
 ► While investigators and care providers are blind-
ed to group allocation in stage 3, participants are 
unblinded.
 ► Positive findings will increase OSA awareness and 
treatment in pregnancy.
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such as obesity, type 2 diabetes mellitus, coronary artery 
disease and stroke.3 There are many potential causes of 
FGR, but in the absence of underlying genetic condi-
tions, congenital anomalies or intrauterine infection, 
FGR is typically due to impaired uteroplacental perfu-
sion.2 4 Current assessment is based on repeated ultra-
sound assessments of fetal growth, antenatal testing 
including non- stress test and/or biophysical profile 
(including electronic fetal heart rate monitoring) and 
umbilical artery Doppler velocimetry.5 Intervention is 
limited to antenatal steroid administration and interven-
tional delivery when the risk of stillbirth is deemed too 
high to continue the pregnancy. There is no intervention 
currently available to improve uteroplacental blood flow 
and fetal growth in utero, so there is often no alterna-
tive to interventional delivery.6 When the pregnancy is 
remote from term, interventional delivery exposes an 
already compromised fetus to additional complications of 
prematurity, in particular to neonatal brain injury from 
intraventricular haemorrhage.7 8
Pregnancy is associated with a higher incidence of sleep 
disordered breathing (SDB), a group of chronic condi-
tions involving recurrent episodic partial or complete 
cessation of breathing throughout the night.9 Obstructive 
sleep apnoea (OSA) is an increasingly common form of 
SDB in both the general and pregnant population.10 OSA 
is characterised by complete (apnoea) or incomplete 
(hypopnoea) collapse of the upper airway during sleep 
leading to recurrent episodic cessation or limitation of 
normal breathing. This in turn leads to recurrent oxygen 
desaturation and hypercapnia, frequent night- time 
arousals and excessive daytime sleepiness.11 12
OSA in pregnancy has been associated with poor 
maternal- fetal outcomes, including gestational hyper-
tension, pre- eclampsia, gestational diabetes, FGR, 
low birth weight, preterm delivery and higher rates of 
neonatal intensive care unit (NICU) admission.13–20 
Patients with OSA are more likely to have negative 
neonatal outcomes,21 and severe maternal morbidity 
and mortality,17 regardless of their obesity status. The 
relationship between severity of OSA in pregnancy and 
adverse outcomes is an ongoing area of research.22 
Unfortunately, because few pregnant women are 
referred for polysomnography (PSG), it is likely that 
OSA and other sleep disorders are underdiagnosed,23 
with the OSA- related symptoms of snoring, disrupted 
sleep and fatigue being frequently attributed to tran-
sient features of normal pregnancy.24
Recurrent apnoeic and hypopnoeic episodes are asso-
ciated with intermittent oxygen desaturation and hyper-
capnia. Recurrent hypoxia leads to oxidative stress, 
sympathetic activation and inflammation that may be 
harmful to both the mother and her fetus.25 Acute hyper-
capnia in pregnant mice and rats has been shown to cause 
acute placental hypoperfusion and acute fetal asphyxia.26 
There is very little information about the effect of 
these episodes on the human fetus. One small observa-
tional study demonstrated fetal heart rate decelerations 
accompanying maternal oxyhaemoglobin desaturation,27 
while another found no association.28
Positive airway pressure (PAP) is a common and 
effective treatment for OSA which acts by mechanically 
splinting the upper airway with pressurised air to prevent 
collapse. PAP delivered at a single pressure (continuous 
PAP or CPAP) usually requires a sleep study to identify 
optimal settings; it also cannot respond to changes in 
upper airway function related to changes in habitus, body 
position, sleep stage or other factors. In contrast, auto-
titrating PAP (aPAP) can detect upper airway resistance 
and respond by adjusting the delivered pressure (within 
a selected range). The delivered pressures from aPAP can 
therefore be lower than from CPAP, which makes aPAP 
more tolerable for most patients.29 We use aPAP as the 
intervention for all patients in the Sleep Apnea and Fetal 
Growth Restriction (SAFER) study. However, as much 
of the medical literature is still based on CPAP rather 
than aPAP, we use the generic term PAP throughout the 
remainder of this manuscript.
PAP is a proven low- risk therapeutic intervention for 
patients with OSA in the general, non- obstetric popula-
tion. Multiple studies have shown that PAP use in patients 
with OSA reduces the incidence of death from cardiac- 
related complications including congestive heart failure, 
coronary artery disease, arrhythmia and stroke,30–32 and 
may improve outcomes related to diabetes.33 34 Small 
studies of PAP in pregnant women with severe pre- 
eclampsia and OSA diagnosed by PSG demonstrated 
improved maternal haemodynamic profiles and cardiac 
output35 36 although no obstetric or neonatal outcomes 
were measured.
The hypothesis of the SAFER study is that, in pregnan-
cies complicated by FGR where the mothers have been 
diagnosed with OSA, maternal PAP therapy will improve 
intrauterine fetal growth and birth weight, increase 
randomisation- to- delivery interval and the gestational age 
at delivery and improve neonatal well- being. Ultimately, 
if PAP therapy is shown to improve intrauterine fetal 
growth in pregnancies with OSA and FGR, obstetric prac-
tice would be expected to change. Such a finding would 
lead to a clinical imperative to screen, diagnose and treat 
OSA in pregnancy, particularly in the presence of FGR.
METHODS
Research design overview
The Human Research Protection Office at Washington 
University School of Medicine in St Louis, Missouri, the 
Research Subject Review Board at the University of Roch-
ester, New York, and the Helsinki Committee for Ethics 
in Research in Human Subjects in Hadassah Hebrew 
University Medical Center, Jerusalem, Israel, all approved 
the study. The choice of these sites was determined by the 
location of the principal investigators involved in initia-
tion of this study; however, all sites are academic, high- 
risk obstetric, tertiary referral centres with large numbers 
of pregnancies complicated by FGR. There is wide 
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geographic and demographic diversity between these 
centres, which adds to the generalisability of the study. 
The SAFER study detailed in this protocol adheres to the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials checklist,37 and lists the 24 items in the 
WHO Trial Registration Data Set. The protocol version is 
dated 5 February 2020. The SAFER study is a three- stage 
trial that assesses pregnant patients with diagnosed FGR. 
The overall flow of participants through the SAFER study 
is shown in figure 1.
We enrol women with pregnancies complicated by 
FGR between 22 and 31 weeks of gestation. Stage 1 is 
a brief telephone or in- person questionnaire to identify 
which of these pregnant women are at elevated risk for 
OSA; these women are then recruited into stage 2. Stage 
2 is a prospective observational study using home sleep 
apnoea testing (HSAT) to confirm the diagnosis of OSA. 
Participants meeting OSA diagnostic criteria progress to 
stage 3. Stage 3 is a pragmatic randomised clinical trial 
of PAP as the intervention, versus a control group of 
standard care which does not include PAP. The primary 
outcome of stage 3 is birth weight; secondary outcomes 
include fetal growth velocity on ultrasound, birth weight 
corrected for gestational age, enrolment- to- delivery 
Figure 1 Sleep Apnea and Fetal Growth Restriction (SAFER) study flow chart. AHI, apnoea- hypopnoea index; BMI, body mass 
index; FGR, fetal growth restriction; NICU, neonatal intensive care unit; OSA, obstructive sleep apnoea; PAP, positive airway 
pressure; RCT, randomised controlled trial.
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interval, gestational age at delivery and neonatal 
outcomes.
All three stages of this international, multicentre study 
will be conducted at three academic medical centres, 
which all serve a large and diverse population of high- 
risk obstetric patients. These centres are: Washington 
University School of Medicine in St Louis, Missouri 
(Barnes- Jewish Hospital); University of Rochester, New 
York (Strong Memorial Hospital); and Hadassah Hebrew 
University Medical Center, Jerusalem, Israel (Hadassah 
Hospital, Ein Karem and Hadassah Hospital, Mt Scopus). 
The demographic characteristics of these hospitals are 
summarised in table 1.
There is lack of clarity in current guidelines over the 
use of the term FGR. We use the American College of 
Obstetrics and Gynecology definition of FGR as estimated 
fetal weight below the 10th percentile for a population,5 
and small for gestational age (SGA) as birth weight below 
the 10th percentile.
Patient and public involvement
In an unpublished pilot study completed prior to comple-
tion of this protocol, pregnant volunteers used HSAT as 
described in stage 2, and OSA- positive subjects used PAP 
as described in stage 3. The pilot study allowed investi-
gators to assess the night- time tolerability of both HSAT 
and PAP for participants. Out of 57 patients who received 
HSAT, 52 had data adequate for analysis. Of these 52 
patients, 10 met OSA criteria for PAP use (see below); 
however, one had an urgent delivery before PAP could be 
distributed. Of the remaining nine subjects, one declined 
to use PAP, one could not tolerate it and all the remaining 
seven met PAP adherence criteria (see below). Generally, 
adherence and comfort were good for both HSAT and 
PAP.
As part of the effort to design the study with a toler-
able intervention and a meaningful outcome, two of our 
principal investigators met with community obstetricians, 
primary care physicians and with a non- profit organisa-
tion advocating for high- risk pregnant maternal health, 
in order to discuss the study and obtain feedback well in 
advance of its final iteration.
Study participants
Inclusion criteria
This study enrols participants in a three- stage protocol. 
We enrol pregnant women, aged 18–50 years, who have 
been diagnosed with established FGR. FGR is defined as 
estimated fetal weight <10th percentile based on at least 
one routine second trimester ultrasound without a subse-
quent increase to >15th percentile on any ultrasounds 
prior to enrolment. If the ultrasound that identified FGR 
was performed prior to 21 completed weeks, a repeat 
scan after 22 weeks is required to confirm the diagnosis 
of FGR prior to enrolment. The lower limit of gestational 
age at enrolment to stage 1 is 22+0 weeks; the upper limit 
of gestational age at enrolment to stage 1 is an adequate 
gestational age to be able to complete stages 1 and 2 and, 
if appropriate, to receive stage 3 intervention by no later 
than 32+0 weeks.
Exclusion criteria
The following exclusion criteria apply at the time of 
enrolment: prespecified independent cause of FGR 
(congenital or genetic anomalies, suspected aneuploidy 
with two minor or one major markers, intrauterine infec-
tion or multiple gestation); active labour; a concrete deci-
sion already made to induce labour or perform caesarean 
delivery within 2 days; reverse end- diastolic flow in the 
umbilical artery (note that other abnormal Doppler flow 
velocities such as absent end- diastolic flow in the umbilical 
artery or uterine artery notching or increased pulsatility 
index are not exclusion criteria unless other exclusion 
criteria are present); pre- existing formal diagnosis of 
OSA; chronic pulmonary disease; haemoglobinopathies 
(including thalassemia major and sickle cell disease, but 
Table 1 Demographic characteristics of the medical centres in the SAFER study (data for 2019)
Institution Deliveries CS rate (%)
US protocol used for 
estimated fetal weight




University of Washington, 
Barnes Jewish Hospital, St 
Louis, Missouri
3576 31.4 Hadlock et al55 A US national reference for fetal 
growth.56
Revised Fenton growth chart 
for preterm infants.57
University of Rochester, 
Strong Hospital, Rochester, 
New York
2859 34.9 Hadlock et al58 Local nomogram from 115 000 
births in the nine- county Finger 
Lakes Region, 2004–2013.59 
60 (For Rochester birthweight 
nomogram see online 
supplemental file 2).
Local nomogram from 
115 000 births in the 
nine- county Finger Lakes 
Region, 2004–2013.59 60 
(For Rochester birthweight 
nomogram see online 
supplemental file 2).
Hadassah Hebrew University 





17.1 Hadlock et al58 International estimated fetal 
weight standards of the 
INTERGROWTH- 21st Project.61
Birthweight standards in the 





CS, caesarean section; FGR, fetal growth restriction; SAFER, Sleep Apnea and Fetal Growth Restriction; SGA, small for gestational age; US, ultrasound.
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not sickle trait or thalassemia minor without clinical mani-
festations); maternal craniofacial anomalies which might 
impair the ability of the participant to use PAP appliances; 
lack of proficiency in English (Rochester or St Louis) or 
either Hebrew, Arabic or English (Jerusalem); inability to 
understand the consent; and unwillingness or inability to 
participate adequately in OSA screening (stage 1) or in 
HSAT (stage 2). Note that poor adherence to PAP (stage 
3) is not an exclusion criterion. PAP usage is recorded but 
outcomes are assessed by intention to treat.
Stage 1: initial screening for OSA risk
Stage 1 of the trial is designed in accordance with the 
Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) statement (https://www. 
strobe- statement. org). Potential participants with FGR as 
defined above are identified through referral from the 
obstetric ultrasound service, directly from the obstetrician 
or by review of the electronic medical record. Those who 
meet inclusion and exclusion criteria are approached for 
consent either by telephone, in the outpatient clinics or 
as inpatients by a member of the research team. Partici-
pants undergo a brief screening questionnaire to assess 
for risk of OSA. Participants are deemed to be at risk for 
OSA if they report loud snoring, report witnessed gasping 
for air during sleep, have an Epworth score >10 or a Facco 
score >75 (see figure 1).20 Participants with evidence of 
OSA risk are invited to proceed to stage 2.
Stage 2: HSAT and OSA screening tools
Participants identified as being at risk for OSA in stage 
1 progress to stage 2. The primary assessment for 
confirming OSA diagnosis in this study is HSAT. Stage 2 
of the trial is an observational study designed in accor-
dance with the STROBE statement (https://www. strobe- 
statement. org/).
Prior to HSAT, participants are assessed for demo-
graphic data, medical comorbidities, body mass index, 
neck circumference and the presence of any craniofacial 
abnormalities. They also undergo a more detailed OSA 
assessment consisting of component parts of five standard 
OSA screening tools (STOP- BANG, Berlin Question-
naire, American Society of Anesthesiologists checklist, 
Flemons Index and Epworth Sleepiness Scale). These 
screening tools for OSA have each been validated in the 
non- pregnant population; some but not all have been 
validated in pregnancy.20 38 39
HSAT is performed with a Food and Drug 
Administration- approved type III home sleep monitor 
(ResMed Apnea Link Air, ResMed, San Diego, Cali-
fornia), which records the following: (1) air flow using 
nasal cannula and pressure transducer; (2) respiratory 
effort using elastic respiratory inductance plethysmog-
raphy belts around the chest and abdomen; (3) ECG; 
and (4) pulse oximetry.40 A trained member of the study 
team shows each study participant how to apply the 
sensors and use the HSAT monitor and instructs her to 
wear the HSAT monitor for two consecutive nights. The 
HSAT monitor data are downloaded, and studies are 
reviewed and scored by a registered polysomnographic 
technologist per standard scoring protocols for apnoea- 
hypopnoea index (AHI) and oxygen desaturation index 
(ODI).41 AHI is defined as the number of apnoeas plus 
hypopnoeas on average each hour.
Hypopnoea is defined by the American Academy of 
Sleep Medicine recommended rule 1A; where a hypop-
noea requires all of the following to be met: (1) the peak 
signal for respiratory excursions drops by ≥30% from 
pre- event baseline; (2) the duration of the ≥30% drop is 
≥10 s; and (3) there is a ≥3% oxygen desaturation from 
pre- event baseline and/or the event is associated with an 
arousal.41 ODI is defined as the number of ≥3% oxygen 
desaturations per hour of sleep without the required 
drop in peak signal excursions.
HSAT generally underestimates AHI compared with 
PSG, as the entire study duration is used as the denom-
inator when calculating AHI. These errors are most 
evident in mild OSA.42 To maximise sensitivity to detect 
OSA yet improve specificity in this pragmatic study, we 
add an ODI ≥5 criterion in cases where AHI is between 5 
and 10. Accordingly, an HSAT that is positive for OSA is 
defined as either an AHI ≥5 with an ODI ≥5 or as an AHI 
≥10 regardless of the ODI.
The second night of HSAT monitoring serves only as a 
backup in case the first night is inadequate to determine 
the AHI and ODI. Variables derived from HSAT include 
AHI, ODI, SaO2 nadir and time with SaO2 <90%. Investi-
gators, treating physicians and participants are blinded 
to these results until after delivery. The only result that is 
unblinded prior to delivery is the binary ‘OSA positive’ 
versus ‘OSA negative’ HSAT result. Participants with an 
HSAT that is positive for OSA will proceed to stage 3. All 
participants from stage 2 are followed through the time 
of delivery and assessed for maternal and fetal outcomes 
after delivery (details below).
Stage 3: randomised trial of PAP therapy
Participants diagnosed with OSA in stage 2 proceed to 
stage 3, which is a randomised controlled trial (RCT) of 
PAP versus standard care control. The RCT is designed in 
accordance with the Consolidated Standards of Reporting 
Trials statement (http://www. consort- statement. org). 
The primary outcome is unadjusted birth weight.
Participants randomised to PAP are asked to use PAP 
whenever sleeping, from the time of randomisation 
until delivery. The PAP device is the ResMed AirSense 
10 ‘AutoSet for Her’, set at the widest pressure range 
of 4–20 cmH2O. The low end of the range is increased 
if the participant indicates discomfort from a sensation 
of insufficient air pressure. During set- up, participants 
select from full face mask, nasal mask or nasal pillow 
interfaces, depending on comfort and fit. Initial set- up 
is performed by a team member with clinical experience 
with PAP treatment. Participants can change their mask 
interfaces ad libitum. Adherence to PAP is continuously 
assessed remotely using a cloud- based monitoring system, 
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Airview (ResMed). In case of malfunction of this system, 
adherence is also recorded by a memory card in each PAP 
device. Adherence is monitored twice in the first week, 
then weekly until the end of the study. We have defined 
acceptable adherence to PAP as ≥4 hours of treatment on 
≥70% of nights from the first night after PAP set- up to 
the night prior to delivery. This definition is based on the 
Centers for Medicare and Medicaid Services guideline.43 
If a participant does not meet this benchmark based on 
the nights studied, she receives a call from a team member 
and is offered a troubleshooting visit to reassess mask fit, 
machine settings and other changes in equipment in 
order to try to improve adherence.
Recruitment, randomisation and blinding
Participant recruitment occurs simultaneously at all 
sites (Barnes- Jewish Hospital, Washington University in 
St Louis; Strong Memorial Hospital, University of Roch-
ester; and Hadassah Hebrew University Medical Center, 
Jerusalem, Israel). Randomised allocation in stage 3 
occurs only after participant enrolment to avoid selec-
tion bias. Randomised allocation is performed centrally 
by random number generator using block randomisation 
with 1:1 allocation to PAP versus non- PAP control, using 
randomised blocks of either two or four participants. 
Randomisation is stratified by study site; within each site, 
blocks are trichotomised by AHI into low (AHI 5–15), 
medium (AHI 16–30) or high (AHI >30) as defined 
above. Only the coordinating- centre study coordinator 
is unblinded to absolute AHI or AHI category. All sites 
produce a weekly report on the number of eligible partic-
ipants, the number of participants approached and the 
number recruited. To aid data homogeneity, a central 
data entry system is used (Research Electronic Data 
Capture; REDCap). At each centre, the investigators have 
a secure password allowing access to the protected data-
base. After randomised allocation, the participant is noti-
fied of her allocation by the site investigator; subjects in 
the PAP group are then instructed on PAP use and a mask 
fitting session is scheduled. Participants are instructed 
not to reveal their group allocation to the technicians 
performing follow- up ultrasounds or to the obstetricians 
making clinical management decisions.
Outcome measures and analysis
Primary outcome
The goal for stage 1 is to identify OSA risk as defined 
above for the purpose of recruiting participants into 
stage 2. The goal for stage 2 is to identify OSA based 
on HSAT criteria as defined above for the purpose of 
recruiting participants into stage 3. The goal for stage 
3, and the primary outcome of the SAFER study, is the 
impact of the randomised treatment intervention (PAP vs 
standard care control) on unadjusted birth weight. Birth 
weight is an endpoint driven by multiple factors including 
intrauterine fetal growth velocity and gestational age 
at delivery. These factors may not be independent of 
each other, as frequently women with severe FGR have 
interventional delivery performed remote from term, 
either for fetal indications or for maternal indications 
(typically when FGR is accompanied by pre- eclampsia). 
The primary endpoint, unadjusted birth weight, will be 
corrected for gestational age and by appropriate racial 
and local nomograms in multivariate analysis.
Secondary outcomes
The secondary outcome of stage 1 is the percentage 
of patients with FGR who screen positive for OSA. The 
secondary outcome for stage 2 is the percentage of patients 
who test positive for OSA in HSAT. These outcomes will 
help determine the clinical feasibility and cost- effectiveness 
of this strategy in the general population. An additional 
secondary outcome of stage 2 is to assess the predictive 
value of each of the OSA screening tools for identifying 
OSA in pregnancy. Secondary outcomes of stage 3 are as 
follows: (1) obstetric outcomes: ultrasound fetal growth 
velocity,44 enrolment- to- delivery interval, gestational age 
at delivery, birth weight (as a Z- score) corrected for gesta-
tional age45 using an algorithm to standardise gestational 
age,46 stillbirth; (2) neonatal outcomes: Apgar score, rate 
of admission to higher levels of care (NICU or special 
care nursery), length of neonatal stay.
Exploratory outcomes of stage 3 are as follows: (1) 
obstetric outcomes: mode of delivery, umbilical cord gases, 
umbilical artery blood flows; (2) maternal outcomes: 
postpartum depression Edinburgh Postnatal Depres-
sion Scale (EPDS) score, rate of hypertensive disorders 
of pregnancy, rate of gestational diabetes mellitus; (3) 
neonatal outcomes: postnatal hypoglycaemia (<40 mg/
dL at any time)47 and/or requirement for intravenous 
glucose treatment based on American Academy of Pedi-
atrics guidelines,48 rates of hypoxic ischaemic neonatal 
encephalopathy, neonatal death in first year of life.
Primary and secondary outcomes are compared 
between the two study groups in stage 3 (OSA- positive 
patients randomised to standard care with no PAP vs 
those randomised to PAP therapy). We use intention- to- 
treat analysis.
Planned subgroup analyses
We plan the following subgroup analyses:
PAP use
The effect of PAP on primary and secondary outcomes 
based not on intention to treat, but rather on PAP adher-
ence (as described above). The clinical justification of 
this subgroup allocation is to assess whether a negative 
or a borderline primary outcome of SAFER may mask a 
true clinical effect of PAP when used with good adher-
ence. This subgroup analysis will also accommodate the 
unlikely crossover of a patient allocated to the no- PAP 
control in stage 3, but who is subsequently referred by 
their primary physician or obstetrician for OSA work- up 
(not current standard of care) and who goes on to receive 
PAP.
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OSA severity
The effect of PAP on primary and secondary outcomes 
with stratification by OSA severity (mild, AHI 5–15; 
moderate, AHI 15–30; severe >30). We hypothesise that 
maternal and fetal outcomes will be most improved 
following PAP therapy in patients with the most severe 
cases of OSA. The clinical justification of this subgroup 
allocation is to assess whether a negative or borderline 
primary outcome of SAFER may mask a true clinical effect 
of PAP when used in patients with more severe OSA; this 
may also aid in the determination of an optimal target 
population based on OSA severity for clinical use of PAP 
in FGR.
Planned exploratory subgroup analyses
PAP use
The effect of PAP usage as a continuous variable (mean 
hours of PAP use per night) on primary and secondary 
outcomes; the purpose of this exploratory subgroup anal-
ysis is to explore the possible dose- response effect of PAP.
OSA severity
The effect of PAP on primary and secondary outcomes 
with stratification by secondary measures from the HSAT: 
ODI, SpO2 nadir and time with SpO2 <90%; where the 
stratification into mild, moderate and severe will be 
determined after examining the distribution of data; 
the purpose of this exploratory subgroup analysis is to 
explore whether other measures of OSA severity, partic-
ularly oxygen desaturation, are useful to direct which 
patients may benefit from PAP therapy.
Effect of untreated OSA
Comparison between OSA- negative patients from stage 2 
versus untreated OSA- positive patients (non- PAP control) 
from stage 3 (we anticipate this will be approximately a 
3:1 ratio); the purpose of this exploratory subgroup anal-
ysis is to assess the deleterious effects of OSA on maternal 
and fetal outcomes in these patients.
Statistical analysis
Data are assessed for normality by visual inspection of 
the frequency plot (histogram) and Q- Q plot of each 
outcome variable and by the Kolmogorov- Smirnov test. 
Normally distributed data are presented as mean (SD); 
non- normally distributed data are presented as median 
(IQR). Our primary outcome (birth weight) (derived from 
stage 3) is assessed by two- tailed parametric t- test (normal 
distribution) or non- parametric Wilcoxon rank- sum test 
(non- normal distribution) as appropriate, using inten-
tion to treat as the grouping variable. The same tests 
are used for other continuous secondary outcome vari-
ables (gestational age at delivery; enrolment- to- delivery 
interval; birth weight corrected for gestational age; 
Apgar and umbilical cord gas). For categorical outcomes 
(higher level nursery admission; stillbirth; compliance 
with PAP), the χ2 test or Fisher’s exact test (if expected 
cells are small) is used as appropriate. Additionally, we 
use a mixed effects regression model to assess the effect 
of PAP on the longitudinal association between estimated 
fetal weight and Doppler ultrasound umbilical artery 
flow, while controlling for maternal, obstetric and fetal 
variables that may affect the primary outcome. Only the 
intercept will be specified as the random component to 
account for any omitted variable. By standard conven-
tion, statistical significance is based on a two- sided p value 
<0.05 to determine the significance of association. Statis-
tical testing is currently planned to use SAS V.9.4 (SAS 
Institute).
Sample size calculation
The baseline birth weight of infants with FGR in the 
population from our primary study centre (Barnes- Jewish 
Hospital, St Louis, Missouri) is 2535±234 g (unpublished 
data). Based on these data, we calculated that 104 eval-
uable participants with OSA will need to be randomised 
to either PAP or control (stage 3) in order to have 90% 
power to detect a 150 g difference in birth weight in the 
PAP group compared with control. This is based on an 
alpha of 0.05, anticipated 5% loss to follow- up and a two- 
tailed t- test.
The risk of OSA in high- risk obstetric populations (such 
as FGR) is as high as 35%.49 As we are screening partic-
ipants for OSA risk by a brief telephone or in- person 
questionnaire (stage 1) prior to HSAT testing (stage 2), 
we estimate that there will be an OSA- positive HSAT in 
30%–50% of these screened participants. Consequently, 
we estimate that we will need to assess HSAT in 200–350 
participants in stage 2 in order to achieve our sample 
size of 104 evaluable participants for stage 3. We estimate 
needing to screen some 500–1000 participants in stage 1 
in order to identify these 200–350 participants for stage 
2. Based on an estimated combined total of 20 000 births 
annually with an estimated incidence of 15% of FGR at 
the above centres, we estimate 3000 pregnancies compli-
cated by FGR each year. Accounting for participants who 
will not meet study inclusion criteria, or will decline to 
participate, the recruitment process is expected to last 
approximately 2 years.
Analysis of pragmatic elements of the SAFER study
The SAFER study is a pragmatic trial. The pragmatic 
elements of the study were quantified using the Prag-
matic Explanatory Continuum Indicator Summary-2 tool 
(https://www. precis- 2. org). Data were obtained from the 
principal investigators in all study centres. According 
to six of the nine criteria, the SAFER study is largely a 
pragmatic study (figure 2). The study is particularly prag-
matic for experimental intervention (a standard commer-
cially available product), follow- up, relevance of clinical 
outcomes and analysis. It is more explanatory for patient 
selection/recruitment and organisational intervention. 
This is because OSA work- up is not currently a standard 
of care for FGR and patients only reach stage 3 if they 
have FGR with HSAT- verified OSA. In this way, the study 
targets patients most likely to experience benefits in fetal 
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growth from PAP, but the generalisability to other popu-
lations may be more limited.
Strengths and limitations
The SAFER study has important strengths. It is a multi-
centre study of a safe, routinely available intervention that 
examines an easily measured outcome with important 
short- term and long- term ramifications for the well- being 
of neonates and possibly for later adult life. SAFER is a 
pragmatic study and the intervention does not preclude 
any existing approaches for the management of these 
high- risk pregnancies. As PAP is worn only when sleeping, 
typically at home, it is relatively easy to keep the research 
team and clinical providers blinded to group allocation. 
As the PAP device used in this study records PAP compli-
ance, we do not have to rely on compliance self- reporting 
which may overestimate nightly device use.
The SAFER study has several limitations. There is 
currently no definitive estimate for the impact of PAP 
on birth weight; hence, the effect measure used in the 
sample size estimation may be inaccurate, which may 
affect the study’s power in regard to our primary and 
secondary endpoints. It is likely that follow- up studies will 
be warranted, especially regarding whether or not the 
results from this specific target population can be gener-
alised to other pregnant women with FGR, or pregnant 
women with OSA who may have pregnancy complications 
without FGR, for example, pre- eclampsia. It is the inten-
tion of the investigators to follow- up a positive result (that 
PAP increases intrauterine fetal growth) with a larger 
study to assess long- term neonatal neurological outcome.
Estimates of fetal weight were all based on the Hadlock 
formula using the standard biometric parameters 
(biparietal diameter, head circumference, abdominal 
circumference, femur length) [52, 53].50 51 However, 
when converting fetal weight to a calculated percentile, 
this must reference a ‘population or customized stan-
dard’.52 As this is a pragmatic multicentre study, each 
study centre defines FGR and SGA by the population 
or customised standard used in their routine care (see 
table 1). This will lead to a slight difference between 
centres in FGR and SGA definition. However, fetal growth 
varies between different ethnic and geographical popula-
tions, so a single absolute imposed standard is of limited 
relevance clinically. The impact of this factor in stage 3 
is reduced by stratification of randomised allocation by 
study centre.
Although investigators, treating physicians and ultra-
sound technicians are blinded to participant group allo-
cation in this study, we do not blind participants. We 
are confident that our primary outcome and all of the 
secondary outcome measures (with the exception of the 
EPDS) can be assessed blindly, which minimises the risk of 
bias. We considered using sham PAP as a placebo control. 
While this could minimise bias in evaluating the effect 
of PAP, wearing an ineffective mask does increase the 
risk of discomfort and sleep disturbances for the control 
group, which potentially biases the results toward the 
active group. A recent study53 demonstrated that there 
was no difference in outcome between sham PAP and a 
device- free control; however, most subjects in the sham 
PAP group guessed correctly that they were receiving the 
placebo intervention.
Home sleep testing may underestimate the true pres-
ence of SDB for several reasons, most notably because it 
Figure 2 Pragmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) wheel for characterising the degree to which 
elements of a study are more explanatory (toward the centre of the wheel) or pragmatic (toward the periphery).
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uses the study duration as the denominator to calculate 
AHI. In addition, in this study, our protocol may be over- 
reliant on oxygen desaturation, as that feature may not be 
as prominent in a young female pregnant population.50 
Hence, our methods may underestimate the true preva-
lence and severity of SDB, and preferentially select the 
study population with more severe SDB. This selected 
population with more severe SDB may have a greater like-
lihood of exhibiting a clinical effect with PAP treatment. 
However, in this pragmatic study, we need to use HSAT 
so that the intervention can be started within as narrow a 
time frame as possible.
This study uses intention- to- treat analysis to assess the 
efficacy of the intervention. The adherence to PAP is rela-
tively low across all populations.51 54 Adherence is gener-
ally higher for aPAP devices, as used in this study, when 
compared with CPAP devices.51 Two recent large national 
database studies reported conflicting results regarding 
gender effects on PAP adherence—either lower in men51 
or lower in women,54 although it is not known whether 
any of these women were pregnant in those studies. It is 
possible that pregnant women concerned about poten-
tially optimising fetal and maternal outcomes would 
be more adherent to PAP. We performed a pilot study 
in preparation for this protocol (see the Patient and 
public involvement section) in which we observed PAP 
adherence in seven out of nine subjects tested. Our 
calculated power does not specifically accommodate 
non- adherence. Accordingly, we also describe a planned 
subgroup analysis in which PAP adherence is used rather 
than intention to treat. Ultimately, this pragmatic study 
can only assess whether administering a PAP device will 
improve outcomes in pregnancy. If PAP is not effective 
during pregnancy because women do not adhere to it, 
that raises a separate question that will require addressing 
separately.
Potential benefits, risks and alternatives
Benefits
All participants reaching stage 2 of the study will poten-
tially benefit from being identified as at risk for OSA and 
being referred to their primary care physician for evalua-
tion by a sleep physician after delivery.
Risks
The likelihood of adverse events in this study is low as 
the devices that will be used in the study (HSAT and 
aPAP) are ones that have been used in the general and 
obstetric population for years. In the unlikely event that 
serious side effects occur, these will be documented and 
reported to the human research protection office and to 
the study’s Data Safety Monitor.
Minimisation of risks to confidentiality
All participants are assigned a unique study ID number. 
The link to identifiers will be destroyed at the end of the 
study. Data will be stored under lock and key (office, file 
cabinet) and only the investigators and research team will 
have access. If data are published, there will be no link to 
identifiers. Study data are not entered into participants’ 
medical records. Data regarding PAP compliance are 
downloaded from ResMed’s secure, cloud- based patient 
management system to a secure server at the primary site 
(Washington University), where they are stored for the 
duration of the study.
Data from this study will be recorded using REDCap, 
a web-based, Health Insurance Portability and Account-
ability Act- compliant application. Access to the data 
is password protected. REDCap servers are housed in 
a secure data centre and information transmission is 
encrypted.
Adverse event reporting and safety monitoring
The research team continuously monitors the study 
for adverse events. All serious adverse events (SAEs) 
are reported to the Institutional Review Board (IRB) 
according to IRB stipulations. Additionally, an attending 
anaesthesiologist at Washington University who is not 
involved in the study serves as the Data Safety Monitor; 
given the small size and relatively low- risk nature of the 
protocol, an individual physician rather than a full Data 
Safety Monitoring Board is used. This monitor reviews all 
adverse events annually and reviews SAEs or unexpected 
adverse events as they occur.
Premature study termination
The only interim analysis to be performed in this study 
will be a single, blinded analysis performed by the Data 
Safety Monitor at the mid- way point, after 52 patients 
have completed stage 3. This interim analysis will assess 
differences between groups in birth weight, gestational 
age at delivery, intrauterine fetal death or reported major 
adverse events. The study code will not be broken, and 
other secondary endpoints will not be assessed. If there is 
a statistically significant difference between groups in one 
of these selected outcomes, then the Data Safety Monitor 
will break the code. If the intervention is associated with 
smaller birth weight, lower gestational age at delivery, 
more intrauterine fetal death or more reported major 
adverse events, then this will be brought to the attention 
of the investigators and the primary study site IRB, for 
consideration of possible premature termination of the 
study on the grounds of increased harm due to the inter-
vention. There will be no premature termination of the 
study due to increased benefit of the intervention. Unless 
there is an increased harm of the intervention, the Data 
Safety Monitor will not give any information to the inves-
tigators regarding the interim analysis.
Ethics and dissemination
Informed consent for stage 1 may be by telephone, elec-
tronic or written consent. Informed consent for stages 2 
and 3 is obtained by a study investigator using electronic 
or written consent (see online supplemental file 1). There 
are no additional risks associated with the screening study 
(stage 1) or the observational HSAT study (stage 2). There 
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is a potential ethical concern regarding randomisation 
of HSAT- positive participants (identified from stage 2 as 
having OSA) to either a PAP (intervention) or a no- PAP 
(control) group. However, this concern is minimised by 
the following arguments: (A) HSAT, or a formal sleep 
study, is not a standard care for investigating FGR, and the 
diagnosis of OSA is rarely made in pregnancy; hence, the 
diagnosis is only made as a result of this study23 24; (B) PAP 
is not a standard care for sleep disturbance in pregnancy 
as many practitioners and participants rightly or wrongly 
assume that this will improve after delivery,24 while PAP 
is seen as a long- term therapeutic intervention. After 
delivery, participants with AHI ≥5 will be given a standard 
IRB- approved letter along with their HSAT results. This 
information can be presented to their primary care physi-
cian for possible referral to a sleep specialist.
The trial steering committee is responsible for all 
major decisions regarding changes to the protocol. The 
committee communicates these changes to the IRB, the 
trial registry and appropriate parties. Data will be shared 
in keeping with the data sharing statement below. Dissem-
ination plans include presentations at scientific confer-
ences. The results of the SAFER trial will be published in 
a peer- reviewed journal. Dissemination of results to study 
participants and their family members will be available on 
request. Updates and results of the study will be available 
to the public at  ClinicalTrials. gov.
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INFORMED CONSENT DOCUMENT 
 
 
Project Title: Sleep Apnea and Fetal Growth Restriction 
 
Principal Investigator: Ellen Lockhart, MD 
 
Research Team Contact: Liz Wilson 314-454-5967 
 
 
This consent form describes the research study and helps you decide if you want to participate.  It 
provides important information about what you will be asked to do during the study, about the risks and 
benefits of the study, and about your rights and responsibilities as a research participant. By signing this 
form you are agreeing to participate in this study. 
• You should read and understand the information in this document including the procedures, 
risks and potential benefits.  
• If you have questions about anything in this form, you should ask the research team for more 
information before you agree to participate.   
• You may also wish to talk to your family or friends about your participation in this study. 
• Do not agree to participate in this study unless the research team has answered your 
questions and you decide that you want to be part of this study.  
 
 
WHAT IS THE PURPOSE OF THIS STUDY? 
 
This is a research study.  We invite you to participate in this research study because you are 
approximately 22-31 weeks pregnant and have been diagnosed with FGR fetal growth restriction. 
 
The purpose of this research study is to help us understand if autotitrated positive airway pressure 
(aPAP) can improve fetal growth in pregnant woman diagnosed with sleep apnea. aPAP is a machine 
that gently delivers pressurized air, via a mask, to keep your airways free of obstruction as you sleep. 
The air pressure delivered from the machines acts as a splint, keeping your throat open so that you can 
breathe freely through the night.  
 
The aPAP machine is approved by the U.S. Food and Drug Administration for the treatment of patients 
with obstructive sleep apnea (OSA), central and/or mixed apneas or periodic breathing.  
 
The home sleep monitoring device is approved by the U.S. Food and Drug Administration to aid in the 
diagnosis of sleep disordered breathing in adult patients.   
 
WHAT WILL HAPPEN DURING THIS STUDY? 
 
If you decide to participate in this study, you will complete a sleep questionnaire either electronically or 
on paper. You may refuse to answer any question on the questionnaire that makes you uncomfortable, 
but it is pssible that you might not be able to participate in the study, depending on which question it is. 
You will be provided with a home sleep monitoring device and instructed on how to use it. A home 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2021-049120:e049120. 11 2021;BMJ Open, et al. Hincker A
02/05/2020 
  Page 2 of 10 
sleep monitor is a device that monitors your breathing while you sleep and determines whether or not 
you have sleep apnea. You will wear the sleep monitor for two consecutive nights and fill out a short 
sleep survey rating the quality of your sleep. 
 
If the results of your home sleep test meet the study criteria, you will be eligible to advance to the final 
stage of the study, where you will be randomized to either receive an aPAP (auto-titrating positive 
airway pressure) device or no device. 
 
If you are randomized to receive an aPAP device and mask, you will be expected to wear the device 
each night when you sleep for the duration of your pregnancy. The aPAP device will provide data to the 
study team to monitor compliance by indicating the number of hours each night that you wear the 
device.  We will collect the data daily from the device electronically via an internal modem. The data 
transfers automatically and you do not have to do anything to make this happen. A member of the study 
team will remain in contact with you throughout the study to provide support and answer any questions 
or concerns you may have.  
 
You will be provided with both paper instructions and educational videos for using the devices.  
 
We will collect demographic data including name, date of birth, home address, phone number and email 
address, and clinical data such as your height, weight, medical history, expected due date, obstetric 
outcomes and fetal outcomes from your and your baby’s medical record.  
 
We are looking for any connections between sleep apnea and low blood flow to your baby. It is routine 
practice for doctors of patients with fetal growth restriction to send the placenta to pathology for 
analysis.  If you agree, we may take a small slice for our research study. 
 
Please place your initials in the blank next to Yes or No for each of the questions below: 
 
You may use a small slice of my placenta tissue to look for genes that might help us to understand 
markers of low blood flow to the placenta   
 
_____ Yes _____ No 
Initials  Initials 
 
 
After your baby is born, we would like to review their medical chart relating to their 18 – 24 month visit 
for the results of a routine test the pediatrician may do called the “Bayley Score.”  The Bayley Score is 
an assessment of your child’s cognition, language and motor function.   
 
Please place your initials in the blank next to Yes or No for each of the questions below: 
 
You may check my child’s electronic medical record for their 18-24-month follow-up visit to 
access the Bayley Score. 
 
_____ Yes _____ No 
Initials  Initials 
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After the study is complete, if the results of your home sleep test meet criteria you will be referred to 
your OB or PCP for a possible referral to a sleep physician. 
 
 
Will you save my research information and/or biospecimens to use in future research studies? 
 
We would like to use the data and tissue we are obtaining in this study for studies going on right now as 
well as studies that are conducted in the future.  These studies may provide additional information that 
will be helpful in understanding fetal growth restriction, or other diseases or conditions, including 
research to develop investigational tests, treatments, drugs or devices that are not yet approved by the 
U.S. Food and Drug Administration.  It is unlikely that what we learn from these studies will have a 
direct benefit to you.  There are no plans to provide financial compensation to you should this occur.  By 
allowing us to use your data and tissue you give up any property rights you may have in the data and 
tissue. 
 
We might remove identifiers from your private information and your data and tissue and then use the 
information and your data and tissue for future research studies or share them with other researchers for 
their future research.  This future research may involve studying genes from your tissue samples. If this 
occurs we will not ask you for additional consent for these uses of your information or data and tissue.  
 
We will share your data and tissue with other researchers. They may be doing research in areas similar 
to this research or in other unrelated areas.  These researchers may be at Washington University, at other 
research centers and institutions, or industry sponsors of research.  We may also share your research data 
with large data repositories (a repository is a database of information) for broad sharing with the 
research community.  If your individual research data is placed in one of these repositories only 
qualified researchers, who have received prior approval from individuals that monitor the use of the 
data, will be able to look at your information.   
 
Your data and tissue will be stored without your name or any other kind of link that would enable us to 
identify which sample(s) or data are yours.  Therefore, it will be available for use in future research 
studies indefinitely and cannot be removed.  
 
HOW MANY PEOPLE WILL PARTICIPATE? 
 
Approximately 34 people will take part in this study conducted by investigators at Washington 
University. Approximately 104 people will take part in the study worldwide.  
 
HOW LONG WILL I BE IN THIS STUDY? 
 
If you agree to take part in this study, your physical involvement will last for the duration of your 
pregnancy, and long-term follow-up will conclude at 18-24 months with the collection of your baby’s 
Bayley scores from EMR.  
 
WHAT ARE THE RISKS OF THIS STUDY? 
 
You may experience one or more of the risks indicated below from being in this study. In addition to 
these, there may be other unknown risks, or risks that we did not anticipate, associated with being in this 
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study.  
 
Home Sleep monitor: You may experience mild discomfort from the device and mild inconvenience. 
 
APAP device: You may experience mild discomfort from the device and mild inconvenience.  A 
properly functioning aPAP device will sense subtle changes in your breathing and adjust itself to the 
best pressure setting for you.  If your machine is malfunctioning, you many not receive adequate 
pressure.  We will be able to see this and can provide you with another. Other risks include: 
 
1. Irritation of facial skin from the PAP mask (common, mild). A mask fitting will be performed by a 
registered sleep technologist, and if skin irritation occurs, you can return for further mask fittings. 
2. Irritation and dryness of nasal passages (common, mild). Every PAP machine will be dispensed with 
a humidifier and filters to minimize irritation and dryness to the nasal passages. 
3. Sensation of fullness in chest (rare, mild): Some individuals feel like the pressurized air from the 
PAP machine causes a sensation of fullness in the chest. This usually resolves spontaneously after 
several days of usage.  
4. Worse sleep quality due to mask on face, noise from machine, or unfamiliar sleeping environment 
(common, mild). This usually resolves as a person gets accustomed to using PAP. 
 
Genetic Research 
There is a federal law called the Genetic Information Nondiscrimination Act (GINA). In general, this 
law makes it illegal for health insurance companies, group health plans and employers with greater than 
15 employees to discriminate against you based on your genetic information. However, it does not 
protect you against discrimination by companies that sell life insurance, disability insurance or long 
term-care insurance. 
 
Breach of Confidentiality 
One risk of participating in this study is that confidential information about you may be accidentally 
disclosed.  We will use our best efforts to keep the information about you secure.  Please see the section 
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WHAT ARE THE BENEFITS OF THIS STUDY? 
 
You may or may not benefit from being in this study. 
 
However, we hope that, in the future, other people might benefit from this study because we will gain a 
better understanding of treatment of obstructive sleep apnea during pregnancy.  
 
WILL IT COST ME ANYTHING TO BE IN THIS STUDY? 
 
You will not have any costs for being in this research study. 
 
You and/or your medical/hospital insurance provider will remain responsible for your regular medical 
care expenses. 
 
WILL I BE PAID FOR PARTICIPATING? 
 
You will be paid for being in this research study. You will need to provide your social security number 
(SSN) in order for us to pay you. You may choose to participate without being paid if you do not wish to 
provide your social security number (SSN) for this purpose.  If your social security number is obtained 
for payment purposes only, it will not be retained for research purposes.    
 
You will receive a $25 Target gift card upon completion of the home sleep study and return of the 
device.  If you are eligible and randomized to wear an aPAP device, you will be given a $25 Target gift 
card for compliance and at $25 Target gift card following return of the device after delivery. You could 
receive up to $75 in Target gift cards if you complete the study and are compliant wearing the aPAP. 
 
WHO IS FUNDING THIS STUDY? 
 
The RESMED Foundation is funding this research study.  This means that Washington University is 
receiving payments from the RESMED Foundation to support the activities that are required to conduct 
the study.  No one on the research team will receive a direct payment or increase in salary from the 
RESMED Foundation for conducting this study. 
 
WHAT IF I AM INJURED AS A RESULT OF THIS STUDY? 
 
Washington University investigators and staff will try to reduce, control, and treat any complications 
from this research. If you feel you are injured because of the study, please contact the investigator Alex 
Hincker at 314-362-2628 and/or the Human Research Protection Office at 1-(800)-438-0445.  
 
Decisions about whether payment for medical treatment for injuries relating to your participation in 
research will be made by Washington University. If you need to seek medical care for a research-related 
injury, please notify the investigator as soon as possible.  
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HOW WILL YOU KEEP MY INFORMATION CONFIDENTIAL? 
 
Other people such as those indicated below may become aware of your participation in this study and 
may inspect and copy records pertaining to this research.  Some of these records could contain 
information that personally identifies you. We will keep your participation in this research study 
confidential to the extent permitted by law.   
• Government representatives (including the Office for Human Research Protections) to complete 
federal or state responsibilities 
• The U.S. Food and Drug Administration 
• The RESMED Foundation  
• Your primary care physician if a medical condition that needs urgent attention is discovered 
• Hospital or University representatives to complete Hospital or University responsibilities 
• Information about your participation in this study may be documented in your health care records 
and will be available to anyone with access to your health care record, including your health 
insurance company.  This information may also be released as part of a release of information 
request. 
• The last four digits of your social security number may be used in hospital or University systems 
to track billing information for research procedures. 
• Washington University’s Institutional Review Board (a committee that oversees the conduct of 
research involving human participants) and the Human Research Protection Office. The 
Institutional Review Board has reviewed and approved this study.  
• Any report or article that we write will not include information that can directly identify you.  
The journals that publish these reports or articles require that we share your information that was 
collected for this study with others to make sure the results of this study are correct and help 
develop new ideas for research. Your information will be shared in a way that cannot directly 
identify you. 
 
To help protect your confidentiality, we will have all paper documents locked in a filing cabinet in a 
locked office of a member of the study team. We will keep all electronic documents on secured servers 
that are password protected and have various state of the art firewall protections with frequent upgrades 
of these protections. Access to these electronic research files will be restricted to members of the 
research team and will be controlled by the principal investigator.  
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. 
Law. This Web site will not include information that can identify you. At most, the Web site will 
include a summary of the results. You can search this Web site at any time.  
 
Are there additional protections for my health information? 
 
Protected Health Information (PHI) is health information that identifies you. PHI is protected by federal 
law under HIPAA (the Health Insurance Portability and Accountability Act). To take part in this 
research, you must give the research team permission to use and disclose (share) your PHI for the study 
as explained in this consent form.  The research team will follow state and federal laws and may share 
your health information with the agencies and people listed under the previous section titled, “How will 
you keep my information confidential?” 
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Once your health information is shared with someone outside of the research team, it may no longer be 
protected by HIPAA.   
 
The research team will only use and share your information as talked about in this form or as permitted or 
required by law.  When possible, the research team will make sure information cannot be linked to you 
(de-identified).  Once information is de-identified, it may be used and shared for other purposes not 
discussed in this consent form. If you have questions or concerns about your privacy and the use of your 
PHI, please contact the University’s Privacy Officer at 866-747-4975.  
 
Although you will not be allowed to see the study information, you may be given access to your health 
care records by contacting your health care provider.  
 
If you decide not to sign this form, it will not affect 
• your treatment or the care given by your health provider. 
• your insurance payment or enrollment in any health plans.   
• any benefits to which you are entitled. 
However, it will not be possible for you to take part in the study. 
 
If you sign this form: 
• You authorize the use of your PHI for this research 
• This authorization does not expire. 
• You may later change your mind and not let the research team use or share your information 
(you may revoke your authorization).  
• To revoke your authorization, complete the withdrawal letter, found in the Participant section 
of the Human Research Protection Office website at 
https://hrpo.wustl.edu/participants/withdrawing-from-a-study/ or you may request that the 
investigator send you a copy of the letter.       
o If you revoke your authorization: 
 The research team may only use and share information already collected for 
the study. 
 Your information may still be used and shared as necessary to maintain the 
integrity of the research, for example, to account for a participant’s 
withdrawal from the research study or for safety reasons. 
 You will not be allowed to continue to participate in the study. 
 
 
Can we contact you by email? 
 
We would like to contact you by email for the purposes listed below.  Some of these emails may contain 
health information that identifies you. 
 
• Patient education 
• Appointment scheduling, which may contain PHI 
 
Only the research team will have access to your email communications.  We will only communicate by 
email to send you the information listed above.  If you have any questions or need to contact us for an 
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urgent or emergent situation, please contact the research team member identified at the top of this 
document. 
 
You should be aware that there are risks associated with sending your health information via email.   
• There is always a risk that the message could be intercepted or sent to the wrong email 
address.  To avoid sending messages to the wrong email address, the first email we send you 
will be a test message to ensure we have the correct email address. 
• When using any computer you should be careful to protect your username and password.  
Make sure you log-out before getting up from the computer.   
• If you share a home computer with other family members, and do not want them to know you 
are participating in this study make sure you provide an email address that only you can 
access.  
• Your employer will have access to any email communications sent or received on any 
electronic devices used for work or through a work server. 
  
Do you agree to allow us to send your health information via email?   
 
_____ Yes  _____ No 
Initials  Initials 
 
IS BEING IN THIS STUDY VOLUNTARY? 
 
Taking part in this research study is completely voluntary.  You may choose not to take part at all.  If 
you decide to be in this study, you may stop participating at any time. Any data that was collected as 
part of your participation in the study will remain as part of the study records and cannot be removed.   
 
If you decide not to be in this study, or if you stop participating at any time, you won’t be penalized or 
lose any benefits for which you otherwise qualify.   
 
What if I decide to withdraw from the study? 
 
You may withdraw by telling the study team you are no longer interested in participating in the study or 
you may send in a withdrawal letter. A sample withdrawal letter can be found at 
https://hrpo.wustl.edu/participants/withdrawing-from-a-study/ under Withdrawing from a Research 
Study. 
 
If you decide to leave the study early, we will ask you to return the home sleep monitor and aPAP 
machines.  
 
If you withdraw from the study we will ask your permission to continue to collect information from your 
health care records. Should this occur we will ask you to sign a separate consent form before collecting 
this information.  
 
Will I receive new information about the study while participating? 
 
If we obtain any new information during this study that might affect your willingness to continue 
participating in the study, we’ll promptly provide you with that information. 
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Can someone else end my participation in this study? 
 
Under certain circumstances, the investigator might decide to end your participation in this research 
study earlier than planned.  This might happen for no reason or because in our judgment it would not be 
safe for you to continue, because funding for the research study has ended, because the sponsor has 
decided to stop the research. 
 
WHAT IF I HAVE QUESTIONS? 
 
We encourage you to ask questions.  If you have any questions about the research study itself, please 
contact: Liz Wilson 314-454-5967. If you experience a research-related injury, please contact: Alex 
Hincker at 314-362-2628. 
 
If you have questions, concerns, or complaints about your rights as a research participant, please contact 
the Human Research Protection Office 1-(800)-438-0445, or email hrpo@wustl.edu.   General 
information about being a research participant can be found on the Human Research Protection Office 
web site, http://hrpo.wustl.edu.  To offer input about your experiences as a research participant or to 
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This consent form is not a contract. It is a written explanation of what will happen during the study if 
you decide to participate. You are not waiving any legal rights by agreeing to participate in this study. 
As a participant you have rights and responsibilities as described in this document and including: 
• To be given enough time before signing below to weigh the risks and potential benefits and 
decide if you want to participate without any pressure from the research team or others. 
• To understand all of the information included in the document, have your questions answered, 
and receive an explanation of anything you do not understand. 
• To follow the procedures described in this document and the instructions of the research team to 
the best of your ability unless you choose to stop your participation in the research study. 
• To give the research team accurate and complete information. 
• To tell the research team promptly about any problems you have related to your participation, or 
if you are unable to continue and wish to stop participating in the research study. 
 
Your signature indicates that this research study has been explained to you, that your questions have 
been answered, and that you agree to take part in this study.  You will receive a signed and dated copy 
of this form. 
 
 












Statement of Person Who Obtained Consent 
 
The information in this document has been discussed with the participant or, where appropriate, with the 
participant’s legally authorized representative.  The participant has indicated that they understand the 








(Name of Person who Obtained Consent - printed) 
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24 408 419 440 485 535 549 567 593 616 636 660 685 700 740 766 776
25 428 446 482 539 615 637 655 696 728 749 775 801 816 870 902 951 1284
26 433 468 508 594 690 716 725 778 816 851 890 911 931 1002 1051 1106 1266
27 436 531 568 669 782 818 840 879 919 963 1000 1026 1051 1122 1169 1236 1360
28 519 651 706 806 906 946 990 1034 1083 1119 1175 1204 1231 1303 1359 1458 1806
29 620 699 813 902 996 1035 1081 1153 1209 1265 1344 1373 1396 1468 1541 1645 2472
30 690 724 871 994 1117 1175 1211 1303 1363 1439 1515 1540 1583 1677 1826 2002 3138
31 860 890 1007 1126 1280 1348 1400 1497 1561 1633 1710 1748 1807 1928 2133 2308 3174
32 1060 1093 1190 1297 1465 1523 1583 1672 1748 1818 1902 1957 2009 2140 2344 2487 2880
33 1189 1252 1347 1500 1677 1730 1784 1872 1959 2038 2127 2189 2250 2416 2616 2817 2980
34 1298 1397 1525 1688 1880 1938 2004 2105 2184 2273 2360 2425 2490 2693 2856 3077 3229
35 1511 1624 1774 1923 2100 2163 2230 2345 2428 2526 2627 2690 2754 2959 3136 3312 3513
36 1793 1902 2025 2170 2332 2400 2462 2577 2675 2778 2890 2954 3024 3222 3440 3576 3753
37 2027 2125 2233 2385 2562 2630 2688 2797 2903 3008 3125 3191 3265 3468 3667 3800 3965
38 2253 2355 2468 2610 2790 2858 2915 3025 3132 3240 3363 3430 3507 3718 3889 4035 4198
39 2474 2580 2690 2823 2993 3063 3121 3231 3339 3445 3565 3632 3710 3915 4082 4230 4382
40 2648 2745 2847 2974 3140 3205 3263 3374 3480 3587 3705 3773 3847 4043 4203 4336 4464
41 2778 2868 2971 3093 3260 3320 3380 3491 3598 3706 3820 3884 3958 4148 4303 4426 4548
42 2866 2946 3042 3174 3340 3403 3482 3596 3705 3831 3943 4009 4088 4298 4463 4555 4657
43 3081 3116 3158 3273 3414 3503 3605 3699 3782 3876 4073 4168 4221 4388
[60] Sheth, T. and J.C. Glantz, Third-Trimester Fetal Biometry and Neonatal Outcomes in Term and Preterm Deliveries. 
J Ultrasound Med, 2016. 35(1): p. 103-10.
[61] Durie, D.E., L.L. Thornburg, and J.C. Glantz, Effect of second-trimester and third-trimester rate of gestational weight gain on maternal and 
neonatal outcomes. Obstet Gynecol, 2011. 118(3): p. 569-75.
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INFORMED CONSENT DOCUMENT 
 
 
Project Title: Sleep Apnea and Fetal Growth Restriction 
 
Principal Investigator: Ellen Lockhart, MD 
 
Research Team Contact: Liz Wilson 314-454-5967 
 
 
This consent form describes the research study and helps you decide if you want to participate.  It 
provides important information about what you will be asked to do during the study, about the risks and 
benefits of the study, and about your rights and responsibilities as a research participant. By signing this 
form you are agreeing to participate in this study. 
• You should read and understand the information in this document including the procedures, 
risks and potential benefits.  
• If you have questions about anything in this form, you should ask the research team for more 
information before you agree to participate.   
• You may also wish to talk to your family or friends about your participation in this study. 
• Do not agree to participate in this study unless the research team has answered your 
questions and you decide that you want to be part of this study.  
 
 
WHAT IS THE PURPOSE OF THIS STUDY? 
 
This is a research study.  We invite you to participate in this research study because you are 
approximately 22-31 weeks pregnant and have been diagnosed with FGR fetal growth restriction. 
 
The purpose of this research study is to help us understand if autotitrated positive airway pressure 
(aPAP) can improve fetal growth in pregnant woman diagnosed with sleep apnea. aPAP is a machine 
that gently delivers pressurized air, via a mask, to keep your airways free of obstruction as you sleep. 
The air pressure delivered from the machines acts as a splint, keeping your throat open so that you can 
breathe freely through the night.  
 
The aPAP machine is approved by the U.S. Food and Drug Administration for the treatment of patients 
with obstructive sleep apnea (OSA), central and/or mixed apneas or periodic breathing.  
 
The home sleep monitoring device is approved by the U.S. Food and Drug Administration to aid in the 
diagnosis of sleep disordered breathing in adult patients.   
 
WHAT WILL HAPPEN DURING THIS STUDY? 
 
If you decide to participate in this study, you will complete a sleep questionnaire either electronically or 
on paper. You may refuse to answer any question on the questionnaire that makes you uncomfortable, 
but it is pssible that you might not be able to participate in the study, depending on which question it is. 
You will be provided with a home sleep monitoring device and instructed on how to use it. A home 
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sleep monitor is a device that monitors your breathing while you sleep and determines whether or not 
you have sleep apnea. You will wear the sleep monitor for two consecutive nights and fill out a short 
sleep survey rating the quality of your sleep. 
 
If the results of your home sleep test meet the study criteria, you will be eligible to advance to the final 
stage of the study, where you will be randomized to either receive an aPAP (auto-titrating positive 
airway pressure) device or no device. 
 
If you are randomized to receive an aPAP device and mask, you will be expected to wear the device 
each night when you sleep for the duration of your pregnancy. The aPAP device will provide data to the 
study team to monitor compliance by indicating the number of hours each night that you wear the 
device.  We will collect the data daily from the device electronically via an internal modem. The data 
transfers automatically and you do not have to do anything to make this happen. A member of the study 
team will remain in contact with you throughout the study to provide support and answer any questions 
or concerns you may have.  
 
You will be provided with both paper instructions and educational videos for using the devices.  
 
We will collect demographic data including name, date of birth, home address, phone number and email 
address, and clinical data such as your height, weight, medical history, expected due date, obstetric 
outcomes and fetal outcomes from your and your baby’s medical record.  
 
We are looking for any connections between sleep apnea and low blood flow to your baby. It is routine 
practice for doctors of patients with fetal growth restriction to send the placenta to pathology for 
analysis.  If you agree, we may take a small slice for our research study. 
 
Please place your initials in the blank next to Yes or No for each of the questions below: 
 
You may use a small slice of my placenta tissue to look for genes that might help us to understand 
markers of low blood flow to the placenta   
 
_____ Yes _____ No 
Initials  Initials 
 
 
After your baby is born, we would like to review their medical chart relating to their 18 – 24 month visit 
for the results of a routine test the pediatrician may do called the “Bayley Score.”  The Bayley Score is 
an assessment of your child’s cognition, language and motor function.   
 
Please place your initials in the blank next to Yes or No for each of the questions below: 
 
You may check my child’s electronic medical record for their 18-24-month follow-up visit to 
access the Bayley Score. 
 
_____ Yes _____ No 
Initials  Initials 
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After the study is complete, if the results of your home sleep test meet criteria you will be referred to 
your OB or PCP for a possible referral to a sleep physician. 
 
 
Will you save my research information and/or biospecimens to use in future research studies? 
 
We would like to use the data and tissue we are obtaining in this study for studies going on right now as 
well as studies that are conducted in the future.  These studies may provide additional information that 
will be helpful in understanding fetal growth restriction, or other diseases or conditions, including 
research to develop investigational tests, treatments, drugs or devices that are not yet approved by the 
U.S. Food and Drug Administration.  It is unlikely that what we learn from these studies will have a 
direct benefit to you.  There are no plans to provide financial compensation to you should this occur.  By 
allowing us to use your data and tissue you give up any property rights you may have in the data and 
tissue. 
 
We might remove identifiers from your private information and your data and tissue and then use the 
information and your data and tissue for future research studies or share them with other researchers for 
their future research.  This future research may involve studying genes from your tissue samples. If this 
occurs we will not ask you for additional consent for these uses of your information or data and tissue.  
 
We will share your data and tissue with other researchers. They may be doing research in areas similar 
to this research or in other unrelated areas.  These researchers may be at Washington University, at other 
research centers and institutions, or industry sponsors of research.  We may also share your research data 
with large data repositories (a repository is a database of information) for broad sharing with the 
research community.  If your individual research data is placed in one of these repositories only 
qualified researchers, who have received prior approval from individuals that monitor the use of the 
data, will be able to look at your information.   
 
Your data and tissue will be stored without your name or any other kind of link that would enable us to 
identify which sample(s) or data are yours.  Therefore, it will be available for use in future research 
studies indefinitely and cannot be removed.  
 
HOW MANY PEOPLE WILL PARTICIPATE? 
 
Approximately 34 people will take part in this study conducted by investigators at Washington 
University. Approximately 104 people will take part in the study worldwide.  
 
HOW LONG WILL I BE IN THIS STUDY? 
 
If you agree to take part in this study, your physical involvement will last for the duration of your 
pregnancy, and long-term follow-up will conclude at 18-24 months with the collection of your baby’s 
Bayley scores from EMR.  
 
WHAT ARE THE RISKS OF THIS STUDY? 
 
You may experience one or more of the risks indicated below from being in this study. In addition to 
these, there may be other unknown risks, or risks that we did not anticipate, associated with being in this 
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study.  
 
Home Sleep monitor: You may experience mild discomfort from the device and mild inconvenience. 
 
APAP device: You may experience mild discomfort from the device and mild inconvenience.  A 
properly functioning aPAP device will sense subtle changes in your breathing and adjust itself to the 
best pressure setting for you.  If your machine is malfunctioning, you many not receive adequate 
pressure.  We will be able to see this and can provide you with another. Other risks include: 
 
1. Irritation of facial skin from the PAP mask (common, mild). A mask fitting will be performed by a 
registered sleep technologist, and if skin irritation occurs, you can return for further mask fittings. 
2. Irritation and dryness of nasal passages (common, mild). Every PAP machine will be dispensed with 
a humidifier and filters to minimize irritation and dryness to the nasal passages. 
3. Sensation of fullness in chest (rare, mild): Some individuals feel like the pressurized air from the 
PAP machine causes a sensation of fullness in the chest. This usually resolves spontaneously after 
several days of usage.  
4. Worse sleep quality due to mask on face, noise from machine, or unfamiliar sleeping environment 
(common, mild). This usually resolves as a person gets accustomed to using PAP. 
 
Genetic Research 
There is a federal law called the Genetic Information Nondiscrimination Act (GINA). In general, this 
law makes it illegal for health insurance companies, group health plans and employers with greater than 
15 employees to discriminate against you based on your genetic information. However, it does not 
protect you against discrimination by companies that sell life insurance, disability insurance or long 
term-care insurance. 
 
Breach of Confidentiality 
One risk of participating in this study is that confidential information about you may be accidentally 
disclosed.  We will use our best efforts to keep the information about you secure.  Please see the section 
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WHAT ARE THE BENEFITS OF THIS STUDY? 
 
You may or may not benefit from being in this study. 
 
However, we hope that, in the future, other people might benefit from this study because we will gain a 
better understanding of treatment of obstructive sleep apnea during pregnancy.  
 
WILL IT COST ME ANYTHING TO BE IN THIS STUDY? 
 
You will not have any costs for being in this research study. 
 
You and/or your medical/hospital insurance provider will remain responsible for your regular medical 
care expenses. 
 
WILL I BE PAID FOR PARTICIPATING? 
 
You will be paid for being in this research study. You will need to provide your social security number 
(SSN) in order for us to pay you. You may choose to participate without being paid if you do not wish to 
provide your social security number (SSN) for this purpose.  If your social security number is obtained 
for payment purposes only, it will not be retained for research purposes.    
 
You will receive a $25 Target gift card upon completion of the home sleep study and return of the 
device.  If you are eligible and randomized to wear an aPAP device, you will be given a $25 Target gift 
card for compliance and at $25 Target gift card following return of the device after delivery. You could 
receive up to $75 in Target gift cards if you complete the study and are compliant wearing the aPAP. 
 
WHO IS FUNDING THIS STUDY? 
 
The RESMED Foundation is funding this research study.  This means that Washington University is 
receiving payments from the RESMED Foundation to support the activities that are required to conduct 
the study.  No one on the research team will receive a direct payment or increase in salary from the 
RESMED Foundation for conducting this study. 
 
WHAT IF I AM INJURED AS A RESULT OF THIS STUDY? 
 
Washington University investigators and staff will try to reduce, control, and treat any complications 
from this research. If you feel you are injured because of the study, please contact the investigator Alex 
Hincker at 314-362-2628 and/or the Human Research Protection Office at 1-(800)-438-0445.  
 
Decisions about whether payment for medical treatment for injuries relating to your participation in 
research will be made by Washington University. If you need to seek medical care for a research-related 
injury, please notify the investigator as soon as possible.  
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HOW WILL YOU KEEP MY INFORMATION CONFIDENTIAL? 
 
Other people such as those indicated below may become aware of your participation in this study and 
may inspect and copy records pertaining to this research.  Some of these records could contain 
information that personally identifies you. We will keep your participation in this research study 
confidential to the extent permitted by law.   
• Government representatives (including the Office for Human Research Protections) to complete 
federal or state responsibilities 
• The U.S. Food and Drug Administration 
• The RESMED Foundation  
• Your primary care physician if a medical condition that needs urgent attention is discovered 
• Hospital or University representatives to complete Hospital or University responsibilities 
• Information about your participation in this study may be documented in your health care records 
and will be available to anyone with access to your health care record, including your health 
insurance company.  This information may also be released as part of a release of information 
request. 
• The last four digits of your social security number may be used in hospital or University systems 
to track billing information for research procedures. 
• Washington University’s Institutional Review Board (a committee that oversees the conduct of 
research involving human participants) and the Human Research Protection Office. The 
Institutional Review Board has reviewed and approved this study.  
• Any report or article that we write will not include information that can directly identify you.  
The journals that publish these reports or articles require that we share your information that was 
collected for this study with others to make sure the results of this study are correct and help 
develop new ideas for research. Your information will be shared in a way that cannot directly 
identify you. 
 
To help protect your confidentiality, we will have all paper documents locked in a filing cabinet in a 
locked office of a member of the study team. We will keep all electronic documents on secured servers 
that are password protected and have various state of the art firewall protections with frequent upgrades 
of these protections. Access to these electronic research files will be restricted to members of the 
research team and will be controlled by the principal investigator.  
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. 
Law. This Web site will not include information that can identify you. At most, the Web site will 
include a summary of the results. You can search this Web site at any time.  
 
Are there additional protections for my health information? 
 
Protected Health Information (PHI) is health information that identifies you. PHI is protected by federal 
law under HIPAA (the Health Insurance Portability and Accountability Act). To take part in this 
research, you must give the research team permission to use and disclose (share) your PHI for the study 
as explained in this consent form.  The research team will follow state and federal laws and may share 
your health information with the agencies and people listed under the previous section titled, “How will 
you keep my information confidential?” 
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Once your health information is shared with someone outside of the research team, it may no longer be 
protected by HIPAA.   
 
The research team will only use and share your information as talked about in this form or as permitted or 
required by law.  When possible, the research team will make sure information cannot be linked to you 
(de-identified).  Once information is de-identified, it may be used and shared for other purposes not 
discussed in this consent form. If you have questions or concerns about your privacy and the use of your 
PHI, please contact the University’s Privacy Officer at 866-747-4975.  
 
Although you will not be allowed to see the study information, you may be given access to your health 
care records by contacting your health care provider.  
 
If you decide not to sign this form, it will not affect 
• your treatment or the care given by your health provider. 
• your insurance payment or enrollment in any health plans.   
• any benefits to which you are entitled. 
However, it will not be possible for you to take part in the study. 
 
If you sign this form: 
• You authorize the use of your PHI for this research 
• This authorization does not expire. 
• You may later change your mind and not let the research team use or share your information 
(you may revoke your authorization).  
• To revoke your authorization, complete the withdrawal letter, found in the Participant section 
of the Human Research Protection Office website at 
https://hrpo.wustl.edu/participants/withdrawing-from-a-study/ or you may request that the 
investigator send you a copy of the letter.       
o If you revoke your authorization: 
 The research team may only use and share information already collected for 
the study. 
 Your information may still be used and shared as necessary to maintain the 
integrity of the research, for example, to account for a participant’s 
withdrawal from the research study or for safety reasons. 
 You will not be allowed to continue to participate in the study. 
 
 
Can we contact you by email? 
 
We would like to contact you by email for the purposes listed below.  Some of these emails may contain 
health information that identifies you. 
 
• Patient education 
• Appointment scheduling, which may contain PHI 
 
Only the research team will have access to your email communications.  We will only communicate by 
email to send you the information listed above.  If you have any questions or need to contact us for an 
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urgent or emergent situation, please contact the research team member identified at the top of this 
document. 
 
You should be aware that there are risks associated with sending your health information via email.   
• There is always a risk that the message could be intercepted or sent to the wrong email 
address.  To avoid sending messages to the wrong email address, the first email we send you 
will be a test message to ensure we have the correct email address. 
• When using any computer you should be careful to protect your username and password.  
Make sure you log-out before getting up from the computer.   
• If you share a home computer with other family members, and do not want them to know you 
are participating in this study make sure you provide an email address that only you can 
access.  
• Your employer will have access to any email communications sent or received on any 
electronic devices used for work or through a work server. 
  
Do you agree to allow us to send your health information via email?   
 
_____ Yes  _____ No 
Initials  Initials 
 
IS BEING IN THIS STUDY VOLUNTARY? 
 
Taking part in this research study is completely voluntary.  You may choose not to take part at all.  If 
you decide to be in this study, you may stop participating at any time. Any data that was collected as 
part of your participation in the study will remain as part of the study records and cannot be removed.   
 
If you decide not to be in this study, or if you stop participating at any time, you won’t be penalized or 
lose any benefits for which you otherwise qualify.   
 
What if I decide to withdraw from the study? 
 
You may withdraw by telling the study team you are no longer interested in participating in the study or 
you may send in a withdrawal letter. A sample withdrawal letter can be found at 
https://hrpo.wustl.edu/participants/withdrawing-from-a-study/ under Withdrawing from a Research 
Study. 
 
If you decide to leave the study early, we will ask you to return the home sleep monitor and aPAP 
machines.  
 
If you withdraw from the study we will ask your permission to continue to collect information from your 
health care records. Should this occur we will ask you to sign a separate consent form before collecting 
this information.  
 
Will I receive new information about the study while participating? 
 
If we obtain any new information during this study that might affect your willingness to continue 
participating in the study, we’ll promptly provide you with that information. 
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Can someone else end my participation in this study? 
 
Under certain circumstances, the investigator might decide to end your participation in this research 
study earlier than planned.  This might happen for no reason or because in our judgment it would not be 
safe for you to continue, because funding for the research study has ended, because the sponsor has 
decided to stop the research. 
 
WHAT IF I HAVE QUESTIONS? 
 
We encourage you to ask questions.  If you have any questions about the research study itself, please 
contact: Liz Wilson 314-454-5967. If you experience a research-related injury, please contact: Alex 
Hincker at 314-362-2628. 
 
If you have questions, concerns, or complaints about your rights as a research participant, please contact 
the Human Research Protection Office 1-(800)-438-0445, or email hrpo@wustl.edu.   General 
information about being a research participant can be found on the Human Research Protection Office 
web site, http://hrpo.wustl.edu.  To offer input about your experiences as a research participant or to 
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This consent form is not a contract. It is a written explanation of what will happen during the study if 
you decide to participate. You are not waiving any legal rights by agreeing to participate in this study. 
As a participant you have rights and responsibilities as described in this document and including: 
• To be given enough time before signing below to weigh the risks and potential benefits and 
decide if you want to participate without any pressure from the research team or others. 
• To understand all of the information included in the document, have your questions answered, 
and receive an explanation of anything you do not understand. 
• To follow the procedures described in this document and the instructions of the research team to 
the best of your ability unless you choose to stop your participation in the research study. 
• To give the research team accurate and complete information. 
• To tell the research team promptly about any problems you have related to your participation, or 
if you are unable to continue and wish to stop participating in the research study. 
 
Your signature indicates that this research study has been explained to you, that your questions have 
been answered, and that you agree to take part in this study.  You will receive a signed and dated copy 
of this form. 
 
 












Statement of Person Who Obtained Consent 
 
The information in this document has been discussed with the participant or, where appropriate, with the 
participant’s legally authorized representative.  The participant has indicated that they understand the 








(Name of Person who Obtained Consent - printed) 
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